Beijing Genomics Institute Signs Multi-Million Dollar Order for 11 Additional Illumina Genome Analyzers
News Apr 23, 2008
BGI is the fourth genome center to expand its Genome Analyzer install base to double digits. As a result of recent enhancements to the Genome Analyzer, BGI researchers will have the capacity to sequence more than two human genomes to 25x coverage per week. This increase in throughput will expand BGI's capacity for sequencing services to the local genetic research labs, as well as broaden the range and pace of sequencing projects undertaken by the organization, such as the YangHuang 99 project, the 1000 Genomes Project, the Giant Panda Project, the tree of life project, and numerous other large-scale initiatives.
"BGI is focused on accelerating the rate of scientific discovery, and expanding our understanding of genetic variation and diversity across human genomes. We have worked closely with Illumina to determine ways to dramatically increase our sequencing capacity in order to efficiently and quickly complete several new large sequencing projects," stated Xiuqing Zhang, Director of the Sequencing Division of the Beijing Genomics Institute.
"After rigorously testing this sequencing platform, we opted to purchase the additional Genome Analyzers because of the machine's enhanced level of performance, price, and ease of use. Combined with the longer 500bp reads from other platforms, Illumina is the most suitable high throughput sequencing platform for accurate de novo genome sequencing. The collaborative relationship that we established with Illumina this past year also played a significant role in our decision to scale up to 17 Genome Analyzers," Zhang added.
Designed for facilities of all sizes, the Genome Analyzer has experienced rapid adoption across genome centers worldwide, including individual research labs, core and service facilities, and biotechnology and pharmaceutical companies. Specified to generate more than three gigabases of high-quality data over a five-day paired-end read run, the Genome Analyzer offers the highest rate of daily output and the simplest and most user friendly workflow.
The Genome Analyzer also offers the broadest set of supported applications, including those used to profile and discover novel miRNA, to create a high-resolution genome-wide map of DNA-protein binding sites, or to sequence a whole-human genome to greater than 30x coverage. The system's capabilities are further validated by the continuing stream of customer peer-reviewed publications, now numbering more than 50.
CRISPR Screening Reveals Sickle Cell Disease TargetNews
A key signaling protein, known as heme-regulated inhibitor (HRI), has been identified as a potential therapeutic target for the development of drugs to treat sickle cell disease, using a CRISPR screening approach.READ MORE
DNA Methylation Related to Liver Disease in Obese PatientsNews
DNA methylation implicated in initiation of liver fibrosis in non-alcoholic fatty liver diseaseREAD MORE
UCL Technology Fund Investment MeiraGTx Raises $75 Million in IPONews
MeiraGTx Holdings plc raised $75 million of gross proceeds upon close of the company’s initial public offering (IPO).READ MORE
International Conference on Neurooncology and Neurosurgery
Sep 17 - Sep 18, 2018